概念性玻璃体内注射治疗病理性近视继发脉络膜新生血管的预后因素。

IF 1.4 4区 医学 Q3 OPHTHALMOLOGY
Yeqiang Shi, Hui Yao, Peng Zhang, Jun Yang, Lei Gao
{"title":"概念性玻璃体内注射治疗病理性近视继发脉络膜新生血管的预后因素。","authors":"Yeqiang Shi, Hui Yao, Peng Zhang, Jun Yang, Lei Gao","doi":"10.1177/11206721251351496","DOIUrl":null,"url":null,"abstract":"<p><p>PurposeChoroidal neovascularization secondary to pathologic myopia (PM-CNV) is an important main factor leading to decreased vision in patients with pathologic myopia. Conbercept, an anti-VEGF drug, is currently the primary treatment for PM-CNV. This study used optical coherence tomography angiography (OCTA) data to investigate the factors influencing the visual prognosis of patients with PM-CNV.MethodsData from patients with PM-CNV diagnosed in the Department of Ophthalmology of The Second People's Hospital of Jinan City from January 2019 to December 2022 were retrospectively analyzed. All patients received intravitreal injections of 0.05 ml Conbercept (0.5 mg) following a 1 + pro re nata (PRN) regimen. Patients were divided into two groups based on visual acuity at 12 months after treatment: improved (best-corrected visual acuity [BCVA] improvement > 1 line) and non-improved (BCVA improvement ≤ 1 line or reduced visual acuity). The factors BCVA after treatment were analyzed using logistic regression analysis.ResultsTwelve months after treatment, there were 77 patients in the improved group and 23 in the non-improved group. Multivariable logistic regression analysis revealed that age (odds ratio (OR) = 1.303, 95% confidence interval (CI): 1.059-1.603, <i>P</i> = 0.012), baseline BCVA (OR = 15.939, 95% CI: 2.490-102.013, <i>P</i> = 0.003), subfoveal CNV (OR = 0.055, 95% CI: 0.010-0.312, <i>P</i> = 0.001), and well-organized CNV (OR = 0.049, 95% CI: 0.009-0.276, <i>P</i> = 0.001) were independently associated with the efficacy of intravitreal injection of conbercept in patients with PM-CNV.ConclusionPoor postoperative BCVA recovery in patients with PM-CNV after conbercept intravitreal injection could be associated with age, baseline BCVA, and location and morphology of CNV.</p>","PeriodicalId":12000,"journal":{"name":"European Journal of Ophthalmology","volume":" ","pages":"11206721251351496"},"PeriodicalIF":1.4000,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Prognostic factors of conbercept intravitreal injection in the treatment of choroidal neovascularization secondary to pathologic myopia.\",\"authors\":\"Yeqiang Shi, Hui Yao, Peng Zhang, Jun Yang, Lei Gao\",\"doi\":\"10.1177/11206721251351496\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>PurposeChoroidal neovascularization secondary to pathologic myopia (PM-CNV) is an important main factor leading to decreased vision in patients with pathologic myopia. Conbercept, an anti-VEGF drug, is currently the primary treatment for PM-CNV. This study used optical coherence tomography angiography (OCTA) data to investigate the factors influencing the visual prognosis of patients with PM-CNV.MethodsData from patients with PM-CNV diagnosed in the Department of Ophthalmology of The Second People's Hospital of Jinan City from January 2019 to December 2022 were retrospectively analyzed. All patients received intravitreal injections of 0.05 ml Conbercept (0.5 mg) following a 1 + pro re nata (PRN) regimen. Patients were divided into two groups based on visual acuity at 12 months after treatment: improved (best-corrected visual acuity [BCVA] improvement > 1 line) and non-improved (BCVA improvement ≤ 1 line or reduced visual acuity). The factors BCVA after treatment were analyzed using logistic regression analysis.ResultsTwelve months after treatment, there were 77 patients in the improved group and 23 in the non-improved group. Multivariable logistic regression analysis revealed that age (odds ratio (OR) = 1.303, 95% confidence interval (CI): 1.059-1.603, <i>P</i> = 0.012), baseline BCVA (OR = 15.939, 95% CI: 2.490-102.013, <i>P</i> = 0.003), subfoveal CNV (OR = 0.055, 95% CI: 0.010-0.312, <i>P</i> = 0.001), and well-organized CNV (OR = 0.049, 95% CI: 0.009-0.276, <i>P</i> = 0.001) were independently associated with the efficacy of intravitreal injection of conbercept in patients with PM-CNV.ConclusionPoor postoperative BCVA recovery in patients with PM-CNV after conbercept intravitreal injection could be associated with age, baseline BCVA, and location and morphology of CNV.</p>\",\"PeriodicalId\":12000,\"journal\":{\"name\":\"European Journal of Ophthalmology\",\"volume\":\" \",\"pages\":\"11206721251351496\"},\"PeriodicalIF\":1.4000,\"publicationDate\":\"2025-06-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Ophthalmology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/11206721251351496\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/11206721251351496","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的病理性近视继发脉络膜新生血管是导致病理性近视患者视力下降的重要因素。Conbercept是一种抗vegf药物,目前是PM-CNV的主要治疗方法。本研究利用光学相干断层血管造影(OCTA)数据探讨影响PM-CNV患者视觉预后的因素。方法回顾性分析2019年1月至2022年12月济南市第二人民医院眼科诊断的PM-CNV患者资料。所有患者在1 + pro re nata (PRN)方案后接受玻璃体内注射0.05 ml Conbercept (0.5 mg)。根据治疗后12个月的视力分为改善组(最佳矫正视力[BCVA]改善bbb1线)和非改善组(BCVA改善≤1线或视力降低)。采用logistic回归分析治疗后BCVA的影响因素。结果治疗12个月后,改善组77例,未改善组23例。多变量logistic回归分析显示,年龄(优势比(OR) = 1.303, 95%可信区间(CI): 1.059 ~ 1.603, P = 0.012)、基线BCVA (OR = 15.939, 95% CI: 2.490 ~ 102.013, P = 0.003)、中央窝下CNV (OR = 0.055, 95% CI: 0.010 ~ 0.312, P = 0.001)、组织良好的CNV (OR = 0.049, 95% CI: 0.009 ~ 0.276, P = 0.001)与PM-CNV患者玻璃体内注射conberept的疗效独立相关。结论妊娠期PM-CNV患者玻璃体内注射后BCVA恢复不良可能与年龄、基线BCVA、CNV的位置和形态有关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Prognostic factors of conbercept intravitreal injection in the treatment of choroidal neovascularization secondary to pathologic myopia.

PurposeChoroidal neovascularization secondary to pathologic myopia (PM-CNV) is an important main factor leading to decreased vision in patients with pathologic myopia. Conbercept, an anti-VEGF drug, is currently the primary treatment for PM-CNV. This study used optical coherence tomography angiography (OCTA) data to investigate the factors influencing the visual prognosis of patients with PM-CNV.MethodsData from patients with PM-CNV diagnosed in the Department of Ophthalmology of The Second People's Hospital of Jinan City from January 2019 to December 2022 were retrospectively analyzed. All patients received intravitreal injections of 0.05 ml Conbercept (0.5 mg) following a 1 + pro re nata (PRN) regimen. Patients were divided into two groups based on visual acuity at 12 months after treatment: improved (best-corrected visual acuity [BCVA] improvement > 1 line) and non-improved (BCVA improvement ≤ 1 line or reduced visual acuity). The factors BCVA after treatment were analyzed using logistic regression analysis.ResultsTwelve months after treatment, there were 77 patients in the improved group and 23 in the non-improved group. Multivariable logistic regression analysis revealed that age (odds ratio (OR) = 1.303, 95% confidence interval (CI): 1.059-1.603, P = 0.012), baseline BCVA (OR = 15.939, 95% CI: 2.490-102.013, P = 0.003), subfoveal CNV (OR = 0.055, 95% CI: 0.010-0.312, P = 0.001), and well-organized CNV (OR = 0.049, 95% CI: 0.009-0.276, P = 0.001) were independently associated with the efficacy of intravitreal injection of conbercept in patients with PM-CNV.ConclusionPoor postoperative BCVA recovery in patients with PM-CNV after conbercept intravitreal injection could be associated with age, baseline BCVA, and location and morphology of CNV.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
3.60
自引率
0.00%
发文量
372
审稿时长
3-8 weeks
期刊介绍: The European Journal of Ophthalmology was founded in 1991 and is issued in print bi-monthly. It publishes only peer-reviewed original research reporting clinical observations and laboratory investigations with clinical relevance focusing on new diagnostic and surgical techniques, instrument and therapy updates, results of clinical trials and research findings.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信